570 filings
Page 4 of 29
EFFECT
526ur27n4rixj
24 May 21
Notice of effectiveness
12:15am
CORRESP
k544zbkp
19 May 21
Correspondence with SEC
12:00am
UPLOAD
xvo1n
18 May 21
Letter from SEC
12:00am
8-K
48nlda
13 May 21
Infinity Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Company Update
4:08pm
8-K
q58dvo0bryry
16 Mar 21
Infinity Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Update on MARIO-275 and Advanced Urothelial Cancer
4:07pm
8-K
tv5x czl3k6lo
12 Feb 21
Infinity Announces Proposed Public Offering of Common Stock
4:44pm
424B5
qf1n mjzx
12 Feb 21
Prospectus supplement for primary offering
4:40pm
S-3MEF
e3dtj58ns2jfs3ws9zns
11 Feb 21
Registration of additional securities for an S-3
9:55pm
424B5
hyr x7bgjxn
11 Feb 21
Prospectus supplement for primary offering
4:06pm
8-K
z5duz8eujl2k1zd
11 Feb 21
Regulation FD Disclosure
7:16am
8-K
x7qdq4
6 Jan 21
Infinity Pharmaceuticals Provides Update for Eganelisib in Patients with Metastatic
9:17am
8-K
2esyavl0nb4tjdd
9 Dec 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9:13am
8-K
d1ncg1 lz
9 Nov 20
Infinity Pharmaceuticals Provides Company Update and Third Quarter 2020 Financial Results
4:16pm
8-K
exok 8haanfm68
29 Sep 20
Infinity Receives Fast Track Designation for Eganelisib in Combination with a Checkpoint
7:41am
8-K
ggm d6q9c
25 Aug 20
Other Events
8:05am